This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Zheng H, Zhang Y, Pan J, Liu N, Qin Y, Qiu L, et al. The role of type 2 innate lymphoid cells in allergic diseases. Front Immunol. 2021;12:586078.
Clottu AS, Humbel M, Fluder N, Karampetsou MP, Comte D. Innate lymphoid cells in autoimmune diseases. Front Immunol. 2021;12:789788.
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell 2018;174:1054–66.
Fukushima K, Satoh T, Sugihara F, Sato Y, Okamoto T, Mitsui Y, et al. Dysregulated expression of the nuclear exosome targeting complex component Rbm7 in nonhematopoietic cells licenses the development of fibrosis. Immunity 2020;52:542–56.
Satoh T, Nakagawa K, Sugihara F, Kuwahara R, Ashihara M, Yamane F, et al. Identification of an atypical monocyte and committed progenitor involved in fibrosis. Nature 2017;541:96–101.
Zhang J, Qiu J, Zhou W, Cao J, Hu X, Mi W, et al. Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity. Nat Immunol. 2022;23:237–50.
Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, et al. Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol. 2018;19:1093–9.
Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringner M, Williams TC, et al. Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing. Cell Res. 2021;31:554–68.
Nakatsuka Y, Yaku A, Handa T, Vandenbon A, Hikichi Y, Motomura Y, et al. Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by regnase-1. Eur Respir J. 2021;57:2000018.
Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–88.
Wijsenbeek MS, Kool M, Cottin V. Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end. Eur Respir J. 2018;52:1802111.
We thank Susan Zunino, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
This work was supported, in part, by AMED (grant numbers JP20fk0108129, JP21fk0108129h0702, and JP21lm0203007), a GSK Research grant (grant number A-32), JSPS KAKENHI (grant numbers JP21K16118 and JP21K08194), the Smoking Research Foundation (grant number 2021Y007), the Takeda Science Foundation, the Uehara Memorial Foundation (grant number 202110055), the MSD Life Science Foundation (grant number RA-026), the Japanese Respiratory Society Boehringer Ingelheim Research Grant Program, and the Japan Intractable Diseases (Nanbyo) Research Foundation (grant number 2020B02).
The authors declare that they have no competing financial interests. The funders had no role in the writing of the manuscript or in the decision to publish the results.
About this article
Cite this article
Nii, T., Fukushima, K. & Kida, H. Specific targeting of lung ILC2s via NRP1 in pulmonary fibrosis. Cell Mol Immunol 19, 869–871 (2022). https://doi.org/10.1038/s41423-022-00867-0